ARCHIVES

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | November 25, 2011

Download PDF Visit The Full Archive

Related Articles

Gregory Reaman Named Associate Director of FDA Office of Oncology Drug Products

June 3, 2011

Maryland’s Greenebaum Cancer Center Wins NCI Designation.

September 12, 2008

University of Kansas Cancer Center Receives NCI Center Designation

July 13, 2012

NCI Chief Operating Officer Lawrence Ray To Retire

April 24, 2009

The 99th turned Out Well For Cancer Program, But Several Important Issues Await 100th Congress

October 31, 1986

Bill Pressures HCFA To Launch Project On Reimbursement for Cancer Trials

July 26, 1996